Current Neuro-Oncology


Volume 24 Number 22
30 November 2022


Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 22, 30 November






Barciszewska AM, Belter A, Gawrońska I, Giel-Pietraszuk M, Naskręt-Barciszewska MZ.
Cross-reactivity between histone demethylase inhibitor valproic acid and DNA methylation in glioblastoma cell lines.
Front Oncol. 2022 Nov 16, 2022;12:1033035
. doi: 10.3389/fonc.2022.1033035. PMID: 36465345. Laboratory investigation.




Shiney TSS, Jerome SA.
An Intelligent System to Enhance the Performance of Brain Tumor Diagnosis from MR Images.
J Digit Imaging. 2022 Nov 16. doi: 10.1007/s10278-022-00715-7. PMID: 36385675. Laboratory investigation˰




Gamboa NT, Crabb B, Henson JC, Cole KL, Weaver BD, Karsy M, Jensen RL.
High-grade glioma imaging volumes and survival: a single-institution analysis of 101 patients after resection using intraoperative MRI.
J Neurooncol. 2022 Nov 17. doi: 10.1007/s11060-022-04159-5. PMID: 36394718. Observational study.




Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, Salacz ME, D'Andre S, Aiken RD, Moshel YA, Nam JY, Pillainayagam CP, Wagner SA, Walter KA, Chaudary R, Goldlust SA, Lee IY, Bota DA, Elinzano H, Grewal J, Lillehei K, Mikkelsen T, Walbert T, Abram S, Brenner AJ, Ewend MG, Khagi S, Lovick DS, Portnow J, Kim L, Loudon WG, Martinez NL, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Giglio P, Gligich O, Krex D, Lindhorst SM, Lutzky J, Meisel HJ, Nadji-Ohl M, Sanchin L, Sloan A, Taylor LP, Wu JK, Dunbar EM, Etame AB, Kesari S, Mathieu D, Piccioni DE, Baskin DS, Lacroix M, May SA, New PZ, Pluard TJ, Toms SA, Tse V, Peak S, Villano JL, Battiste JD, Mulholland PJ, Pearlman ML, Petrecca K, Schulder M, Prins RM, Boynton AL, Bosch ML.
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5370. PMID: 36394838. Interventional study.




Burdett KB, Unruh D, Drumm M, Steffens A, Lamano JB, Judkins J, Schwartz M, Javier R, Amidei C, Lipp ES, Peters KB, Lai A, Eldred BSC, Heimberger AB, McCortney K, Scholtens DM, Horbinski C.
Determining venous thromboembolism risk in patients with adult-type diffuse glioma.
Blood. 2022 Nov 18, 2022:blood.2022017858. doi: 10.1182/blood.2022017858. PMID: 36399711. Laboratory investigation˰




Dean JA, Tanguturi SK, Cagney D, Shin KY, Youssef G, Aizer A, Rahman R, Hammoudeh L, Reardon D, Lee E, Dietrich J, Tamura K, Aoyagi M, Wickersham L, Wen PY, Catalano P, Haas-Kogan D, Alexander BM, Michor F.
Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity.
Neuro Oncol. 2022 Nov 19, 2022:noac253. doi: 10.1093/neuonc/noac253. PMID: 36402744. Interventional study˰




Chen F, Chao M, Huang T, Guo S, Zhai Y, Wang Y, Wang N, Xie X, Wang L, Ji P.
The role of preoperative inflammatory markers in patients with central nervous system tumors, focus on glioma.
Front Oncol. 2022 Nov 22, 2022;12:1055783
. doi: 10.3389/fonc.2022.1055783. PMID: 36483052. Observational study.




Chen J, Wang T, Liu W, Qiu H, Zhang N, Chen X, Ding X, Zhang L.
Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study.
Front Oncol. 2022 Nov 22, 2022;12:1000501
. doi: 10.3389/fonc.2022.1000501. PMID: 36483042. Observational study.




Chiba K, Aihara Y, Oda Y, Fukui A, Tsuduki S, Saito T, Nitta M, Muragaki Y, Kawamata T.
Photodynamic therapy for malignant brain tumors in children and young adolescents.
Front Oncol. 2022 Nov 24, 2022;12:957267
. doi: 10.3389/fonc.2022.957267. PMID: 36505805. Interventional study.




Chen L, Ma J, Zou Z, Liu H, Liu C, Gong S, Gao X, Liang G.
Clinical characteristics and prognosis of patients with glioblastoma: A review of survival analysis of 1674 patients based on SEER database.
Medicine (Baltimore). 2022 Nov 25, 2022;101(47):e32042
. doi: 10.1097/MD.0000000000032042. PMID: 36451503.Observational study.




Gerritsen JKW, Zwarthoed RH, Kilgallon JL, Nawabi NL, Versyck G, Jessurun CAC, Pruijn KP, Fisher FL, Larivière E, Solie L, Mekary RA, Satoer DD, Schouten JW, Bos EM, Kloet A, Nandoe Tewarie R, Smith TR, Dirven CMF, De Vleeschouwer S, Vincent AJPE, Broekman MLD.
Impact of maximal extent of resection on postoperative deficits, patient functioning and survival within clinically important glioblastoma subgroups.
Neuro Oncol. 2022 Nov 24, 2022:noac255. doi: 10.1093/neuonc/noac255. PMID: 36420703. Observational study.




Escobar-Vidarte OA, Griswold DP, Orozco-Mera J, Mier-Garcia JF, Peralta Pizza F.
A Case Series of Stereotactic Biopsy of Brainstem Lesions through the Transfrontal Approach.
J Neurol Surg Rep. 2022 Nov 25, 2022;83(4):e123-e128
. doi: 10.1055/s-0042-1758696. PMID: 36467870. Case report.




Gao Q, Zhou H, Wang G, Ma Z, Li J, Wang H, Sun G, Xue X.
A Model for Predicting Clinical Prognosis in Patients with WHO Grade 2 Glioma.
J Oncol. 2022 Nov 26, 2022;2022:2795939
. doi: 10.1155/2022/2795939. PMID: 36471886. Observational study.




Zhang B, Wan W, Li Z, Gao Z, Ji N, Xie J, Wang J, Wang B, Lai-Wan Kwong D, Guan X, Gao S, Zhao Y, Lu Y, Zhang L, Rodland KD, Tsang SX.
A prognostic risk model for glioma patients by systematic evaluation of genomic variations.
iScience. 2022 Nov 26, 2022;25(12):105681
. doi: 10.1016/j.isci.2022.105681. PMID: 36536675. Observational study.




Pokhylevych H, Khose S, Amer A, Alhasan H, Kaya D, Johnson R, Fuller G, Gruschkus SK, Zaky W, Weinberg JS, Johnson JM.
Retrospective Analysis of Imaging Characteristics of Tectal Gliomas.
J Comput Assist Tomogr. 2022 Nov 27
. doi: 10.1097/RCT.0000000000001391. PMID: 36598462. Observational study.




Peters S, Frisch S, Stock A, Merta J, Bäumer C, Blase C, Schuermann E, Tippelt S, Bison B, Frühwald M, Rutkowski S, Fleischhack G, Timmermann B.
Proton Beam Therapy for Pediatric Tumors of the Central Nervous System-Experiences of Clinical Outcome and Feasibility from the KiProReg Study.
Cancers (Basel). 2022 Nov 28, 2022;14(23):5863
. doi: 10.3390/cancers14235863. PMID: 36497345. Observational study.




Topkan E, Kucuk A, Selek U.
Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide.
J Immunol Res. 2022 Nov 28, 2022;2022:1346094
. doi: 10.1155/2022/1346094. PMID: 36479136. Observational study.